Ascendis Pharma A/S (ASND)
$93.44
-0.76 (-0.81%)
Rating:
Recommendation:
Neutral
| Symbol | ASND |
|---|---|
| Price | $93.44 |
| Beta | 0.863 |
| Volume Avg. | 0.52M |
| Market Cap | 5.214B |
| Shares () | - |
| 52 Week Range | 61.579-178.71 |
| 1y Target Est | - |
| DCF Unlevered | ASND DCF -> | |
|---|---|---|
| DCF Levered | ASND LDCF -> | |
| ROE | -55.14% | Strong Sell |
| ROA | -32.40% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 104.70% | Buy |
| P/E | - | |
| P/B | 6.70 | Strong Buy |
Latest ASND news
About
Download (Excel)Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.